Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease – a case report

References

• Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91–99.10.1016/j.rmed.2016.10.019
   PubMed Web of Science ®Google Scholar
• Hall JC, Casciola-Rosen L, Samedy L, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65(8):1307–1315.10.1002/acr.21992
   PubMed Web of Science ®Google Scholar
• Lega J, Reynaud Q, Belot A, et al. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev. 2015;24(136):216–238.10.1183/16000617.00002015
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. MDA5 autoantibody – another indicator of clinical diversity in dermatomyositis. Ann Transl Med. 2017;5(7):160.10.21037/atm
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, McHugh NJ. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol. 2013;25(6):772–777.10.1097/01.bor.0000434664.37880.ac
   PubMed Web of Science ®Google Scholar
• Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571–1576.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease Lupus. 2016;25(8):925–933.
   Google Scholar
• Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176(2):395–402.10.1111/bjd.14882
   PubMed Web of Science ®Google Scholar
• Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49(9):1726–1733.10.1093/rheumatology/keq153
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Watanabe R, Ishitsuka Y, et al. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636–644.10.1097/BOR.0000000000000329
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.10.1016/j.jaad.2010.09.016
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;2014:290797.
   PubMed Web of Science ®Google Scholar
• Li L, Wang Q, Wen X, et al. Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease. Oncotarget. 2017;8(44):76129–76140.
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu W, Wang Y, et al. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clin Rheumatol. 2015;34(9):1627–1631.10.1007/s10067-015-2935-9
   PubMed Web of Science ®Google Scholar
• Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51(9):1563–1570.10.1093/rheumatology/kes102
   PubMed Web of Science ®Google Scholar
• Isoda K, Kotani T, Takeuchi T, et al. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. Rheumatol Int. 2017;37(8):1335–1340.10.1007/s00296-017-3729-y
   PubMed Web of Science ®Google Scholar
• Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;24(352):h6819.10.1136/bmj.h6819
   Google Scholar
• Suzuki A, Kondoh Y, Taniguchi H, et al. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis. Respir Med Case Rep. 2016;28(19):5–8.
   Google Scholar
• Chino H, Sekine A, Baba T, et al. Radiological and pathological correlation in Anti-MDA5 antibody-positive interstitial lung disease: rapidly progressive perilobular opacities and diffuse alveolar damage. Intern Med. 2016;55(16):2241–2246.10.2169/internalmedicine.55.5774
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49(9):1713–1719.10.1093/rheumatology/keq149
   PubMed Web of Science ®Google Scholar
• Abe Y, Matsushita M, Tada K, et al. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody–positive inflammatory myositis. Rheumatology (Oxford). 2017;56(9):1492–1497.10.1093/rheumatology/kex188
   PubMed Web of Science ®Google Scholar
• Tokunaga K, Hagino N. Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan. Intern Med. 2017;56(11):1399–1403.10.2169/internalmedicine.56.7956
   PubMed Web of Science ®Google Scholar